Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/27/2003US20030220316 Such as N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methyl phenyl)methyl)-4-methoxyphenylacetamide for stimulation of serotonin receptors
11/27/2003US20030220315 Such as 3',3"-dibromo-4',4"-dimethoxy-5',5"-bis-(methoxycarbonyl)-1,1 -diphenylethene; for treating viral diseases/retroviruses
11/27/2003US20030220306 Transcripts harboring inton 1, or fragment thereof; preventing or treating Alzheimer's Disease; ameliorating a neurodegenerative condition; modulating amyloid precursor protein; selectively inhibiting COX-3 or PCOX-1a activity
11/27/2003US20030220303 GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD
11/27/2003US20030220295 Epothilone derivatives
11/27/2003US20030220281 To inhibit the activity of elastase or cathepsin G, thereby inhibiting ectopic implantation of endometrial fragments.
11/27/2003US20030220280 Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration
11/27/2003US20030220268 New phenylalanine derivatives
11/27/2003US20030220256 Truncated 24kDa basic fibroblast growth factor
11/27/2003US20030220255 GLP-1 agonist and cardiovascular complications
11/27/2003US20030220243 A 37 amino acid peptide that is secreted by the L-cells of the intestine in response to food ingestion, because of their ability to stimulate insulin secretion, can be used for the treatment of diabetes, obesity and releated conditions
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030220226 Compounds and compositions for delivering active agents
11/27/2003US20030219909 Materials containing multiple layers of vesicles
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219887 Crystals of glucokinase and methods of growing them
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219874 Comprises endothelial differentiation gene receptor proteins (EDG8) for monitoring receptivity to and/or diagnosing cancer, angiogenesis and inflammation
11/27/2003US20030219499 Therapy of estrogen-associated disorders
11/27/2003US20030219489 Solid pharmaceutical dispersions with enhanced bioavailability
11/27/2003US20030219474 A polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide and a lipid associated with such polynuclotide
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219430 Methods of preventing or treating brain ischemia or brain injury
11/27/2003US20030219428 Deoxyribonuclease formed by genetic engineering, used for prophylaxis respiratory system disorders, lupus erythematosus and/or genetic disorders
11/27/2003US20030219420 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
11/27/2003US20030219403 Compositions and methods of tolerizing a primate to an antigen
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2830619A1 Glucan-based vaccines
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2497601A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
11/27/2003CA2489102A1 Use of quinoline derivatives with anti-integrase effect and applications thereof
11/27/2003CA2486483A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003CA2486302A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486138A1 Methods of using thiazolidinedithione derivatives
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2486092A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003CA2486061A1 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
11/27/2003CA2486000A1 Use of compounds that are effective as selective opiate receptor modulators
11/27/2003CA2485896A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
11/27/2003CA2485847A1 Glucan-based vaccines
11/27/2003CA2485463A1 A direct cellular energy delivery system
11/27/2003CA2485214A1 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2485212A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2485012A1 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
11/27/2003CA2485006A1 Camptothecin derivatives and polymeric conjugates thereof
11/27/2003CA2484702A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003CA2484671A1 Cyanoguanidine prodrugs
11/27/2003CA2484308A1 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
11/27/2003CA2484233A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003CA2483619A1 Novel compounds and their use
11/27/2003CA2483368A1 (s)-4-amino-5-chloro-2-methoxy-n-¬1-¬1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl|-4-piperidinyl|benzamide, process for the preparation thefeof, pharmaceutical composition containing the same, and intermediate therefor
11/27/2003CA2482756A1 Indole derivatives and the use thereof as cb<sb>2</sb> receptor ligands
11/27/2003CA2482348A1 Combinations of an ace inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2471879A1 Pharmaceutical composition containing ghrelin
11/26/2003EP1365030A1 G-protein coupled receptor marker molecules associated with colorectal lesions
11/26/2003EP1364967A2 Glucagon-like insulinotropic peptides, compositions and methods
11/26/2003EP1364958A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof
11/26/2003EP1364957A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof
11/26/2003EP1364953A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
11/26/2003EP1364952A1 Bicyclic nitrogenous fused-ring compound
11/26/2003EP1364950A1 Pyridopyrimidine or naphthyridine derivative
11/26/2003EP1364949A1 Jnk inhibitor
11/26/2003EP1364943A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors
11/26/2003EP1364656A2 Use of bone morphogenetic proteins for healing and repair of connective tissue attachment
11/26/2003EP1364653A1 Casoase 3 inhibitors
11/26/2003EP1364648A1 Cryptotanshinone for preventing and alleviating alzheimer's disease
11/26/2003EP1364586A1 Probiotics and oral tolerance
11/26/2003EP1364051A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
11/26/2003EP1364027A2 Zinc finger binding domains for nucleotide sequence ann
11/26/2003EP1364023A2 Method of diagnosing and treating cartilage disorders
11/26/2003EP1364019A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
11/26/2003EP1364018A2 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
11/26/2003EP1364017A2 Inflammation related g-protein coupled receptor
11/26/2003EP1364014A2 Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
11/26/2003EP1364010A2 Immunomodulatory polynucleotides and methods of using the same
11/26/2003EP1363994A2 Thymic epithelial progenitor cells and uses thereof
11/26/2003EP1363993A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
11/26/2003EP1363950A2 Bispecific monoclonal antibodies to il-12 and il-18 receptors
11/26/2003EP1363948A1 Polypeptide of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids coding therefor and use thereof
11/26/2003EP1363944A2 High-affinity antagonists of elr-cxc chemokines
11/26/2003EP1363940A1 Tumour peptide antigen produced from human mdm2 proto-oncogene
11/26/2003EP1363920A1 Modified psma ligands and uses related thereto
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363912A1 Novel substituted imidazotriazinones
11/26/2003EP1363910A2 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
11/26/2003EP1363908A1 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO 3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM
11/26/2003EP1363907A2 Heterocycle carboxamides as antiviral agents
11/26/2003EP1363906A2 Heterocyclic inhibitors of erk2 and uses thereof
11/26/2003EP1363904A1 Pyrazoles as tgf inhibitors
11/26/2003EP1363901A1 Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles
11/26/2003EP1363900A1 Isoindole-imide compounds as tnf-inhibitors
11/26/2003EP1363899A1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
1 ... 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 ... 1564